Evidence map›Paper›PMID 41760334›Full record

ArticleIn vivo (Athens, Greece)

Long-term Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients With Relapsed/Refractory Multiple Myeloma.

Joon Young Hur, Han-Seung Park, Yunsuk Choi, Hyunkyung Park, Yu-Eun Lee, Jisoo Jeong, Seungah Cha, Eun-Ji Choi, Je-Hwan Lee, Young-Shin Lee and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Joon Young HurDepartment of Hematology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Han-Seung ParkDepartment of Hematology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Yunsuk ChoiDepartment of Hematology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Hyunkyung ParkDepartment of Hematology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Yu-Eun LeeDepartment of Hematology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Jisoo JeongDepartment of Hematology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Seungah ChaDepartment of Hematology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Eun-Ji ChoiDepartment of Hematology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Je-Hwan LeeDepartment of Hematology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Young-Shin LeeDepartment of Hematology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Mijin JeonDepartment of Hematology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Ji Min WooDepartment of Hematology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Young-Ah KangDepartment of Hematology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Hyeran KangDepartment of Hematology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Jung-Hee LeeDepartment of Hematology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea jhleecr@amc.seoul.kr.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimAllogeneic (allo-) hematopoietic cell transplantation (HCT) may confer a survival advantage in a selected population of patients with relapsed and refractory multiple myeloma (R/R MM), however, additional data are needed to identify the patients who will benefit the most. PATIENTS AND

methodsBetween January 2000 and December 2024, 32 patients with R/R MM underwent allo-HCT at the Asan Medical Center, Seoul, Korea, and were included in this retrospective study.

resultsBefore allo-HCT, complete remission (CR) achievement tended to be associated with better overall survival (OS) compared to partial response and refractory status (67.7%

conclusionIn R/R MM after auto-HCT, allo-HCT for patients who attained CR following less than three lines of chemotherapy can still be a promising treatment option with long-term survival.

Indexed as

Hematopoietic Stem Cell TransplantationMultiple MyelomaNeoplasm Recurrence, LocalAdultAgedFemaleHumansMaleMiddle AgedRecurrenceRetrospective StudiesTransplantation ConditioningTransplantation, HomologousTreatment Outcomecumulative incidence of relapsehematopoietic stem cell transplantationMultiple myelomaoverall survival

Identifiers

PMID41760334
PMCPMC12949895

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.